GlassScriptPhysician profile
Hector Delcastillo
NPI 1659489573
$42,075.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $2,020 · 2021: $8,508.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40,570.07 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $339.51 | 2019-2021 | |
| Therapeuticsmd, INC. | $325.51 | 2019-2021 | |
| Lupin INC. | $269.39 | 2019-2021 | |
| Novo Nordisk INC | $131.98 | 2019-2020 | |
| Renovia INC | $70.81 | 2019 | |
| Exeltis, USA INC. | $69.73 | 2019-2021 | |
| Hologic Sales and Service, LLC | $66.10 | 2020-2021 | |
| Allergan, INC. | $59.06 | 2019-2020 | |
| Duchesnay USA Incorporated | $24.11 | 2019 | |
| Ethicon US, LLC | $20.31 | 2020 | |
| Aspira Women'S Health INC | $19.23 | 2019 | |
| Evofem Biosciences, INC. | $16.77 | 2021 | |
| Scynexis, INC. | $15.34 | 2021 | |
| Olympus America INC. | $14.34 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.82 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.53 | 2019 | |
| Sage Therapeutics, LLC | $13.40 | 2019 | |
| Millicent US INC | $11.87 | 2019 | |
| Mylan Pharmaceuticals INC. | $10.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Delcastillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.